Tirzepatide

Tirzepatide is a lab-made peptide that copies two gut hormones at once — GLP-1 and GIP. By mimicking both, it taps into two of the body's natural fullness and metabolism signals together.

It's watched closely because approved medicines like Mounjaro and Zepbound support weight management and blood-sugar control. Researchers study how two hormone signals combined affect metabolism.

Trials behind those approved drugs showed greater weight loss and blood-sugar improvement than many single-hormone approaches. These are established results in approved products.

Distinguishes established clinical findings from early human trials, animal experiments, or laboratory cell culture findings. No human dosing, injection instructions, or treatment recommendations are provided.

Tirzepatide is the active ingredient in FDA-approved Mounjaro and Zepbound. BBOHC supplies a research reference reagent, not an approved medicine.

BBOHC LABS research reagents are non-clinical materials. An FDA approval for a finished medicine containing the same active ingredient does not imply that BBOHC's investigational research vial is FDA-approved.

Gastrointestinal effects in animal assays. Requires standard biohazard laboratory handling.

• Jastreboff AM et al. Tirzepatide Once Weekly for Obesity. N Engl J Med. 2022.

Specific citations are provided for literature context. Product purity & lot verification documentation available on request.